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Renal cell carcinoma (RCC) makes up 2–3% of adult cancers. The introduction of tyrosine kinase inhibitors (TKIs) and mammalian
target of rapamycin inhibitors in the mid-2000s radically changed the management of RCC. These targeted treatments
superseded immunotherapy with interleukin-2 and interferon. The pendulum now appears to be shifting back towards
immunotherapy, with the evidence of prolonged overall survival of patients with metastatic RCC on treatment with the anti-
programmed cell death 1 ligand monoclonal antibody, nivolumab. Clinical prognostic criteria aid prediction of relapse risk for
resected localised disease. Unfortunately, for patients at high risk of relapse, no adjuvant treatment has yet shown benefit,
although further trials are yet to report. Clinical prognostic models also have a role in the management of advanced disease; now
there is a pressing need for predictive biomarkers to direct therapy. Treatment selection for metastatic disease is currently based
on histology, prognostic group and patient preference based on side effect profile. In this article, we review the current medical
and surgical management of localised, oligometastatic and advanced RCC, including side effect management and the evidence
base for management of poor-risk and non-clear cell disease. We discuss recent results from clinical trials and how these are likely
to shape future practice and a renaissance of immunotherapy for renal cell cancer.
Renal cell carcinoma (RCC) represents 2–3% of all adult cancers (Rini
et al, 2009a). It is the seventh most common malignancy in men, and
the ninth in women (Rini et al, 2009a) with 10 144 new cases and
4252 deaths in the United Kingdom per year (Cancer Research UK,
2016). Risk factors include hypertension, smoking, obesity and end-
stage renal disease. With increasing use of radiological investigations,
there has been a steady increase in the rate of incidental diagnosis,
which now accounts for half of all new RCC cases. A third of cases
present with metastatic disease at diagnosis (Gupta et al, 2008) and a
third of those undergoing surgery for early stage disease will relapse,
after a median of 1.9 years (Stewart et al, 2014).
The most common subtype of RCC is clear cell RCC (ccRCC;
70–80%), with papillary (10–15%) and chromophobe tumours (3–
5%) making up the majority of the remainder (Rini et al, 2009a).
Clear cell RCC is characteristically associated with the loss of
function of the VHL (von Hippel-Landau) gene, in the majority of
tumours, whether by somatic mutation, chromosomal loss or
epigenetic silencing (Gossage et al, 2015). The VHL gene is on
chromosome 3p25 and is an established two-hit tumour suppressor
gene; one allele typically inactivated by mutation or promoter
methylation, and the other lost due to a large deletion (Gossage
et al, 2014). The loss of functional VHL protein (pVHL) leads to
the increased expression of hypoxia inducible factors (HIFs) and
the expression of a wide range of genes involved in cancer
progression and metastasis including vascular endothelial growth
factor (VEGF) (Gossage et al, 2015).
In this review, we discuss the latest advances in the management of
local and advanced disease and the rebirth of immunotherapy for RCC.
MANAGEMENT OF EARLY STAGE DISEASE
The expansion in cross-sectional imaging over the last few decades
means that the majority of early stage RCC diagnoses are now the
result of incidental findings. This has led to a debate over how to
best manage small lesions of unknown significance, particularly
in frail, elderly patients in whom the increased competing
cause mortality tips the balance towards active surveillance
(Hollingsworth et al, 2007). Further work is required in terms of
both radiological and serological markers to aid decision-making.
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Localised (T1 and T2) RCC is cured by surgery alone in the
majority of cases with 5-year progression-free survival (PFS) in
patients undergoing surgery for T1 and T2 disease of 95% and
74%, respectively (Russo et al, 2008) (Table 1).
Open radical nephrectomy was for four decades the standard of
surgical care for RCC (Robson et al, 1969). Partial nephrectomy
was initially adopted as a nephron-sparing procedure for selective
indications (solitary kidney and poor renal function), but is now
standard treatment for organ-confined tumours at the renal poles
measuring o7 cm (T1 disease) (Escudier et al, 2014c). In patients
with locally advanced (T3 and T4 disease), there is no proven role
for adrenalectomy or routine lymph node dissection in the absence
of radiological evidence of lymph node or adrenal involvement
(Escudier et al, 2014c).
Laparoscopic approaches for both partial and radical nephrect-
omy are now recommended where technically possible for T1 and
T2 tumours, with the data to suggest equivalent disease control
when compared with open surgery (MacLennan et al, 2012).
Robot-assisted nephrectomy was first described in 2000, and is
increasingly being adopted. The evidence base for robot-assisted
nephrectomy remains limited, with only a single prospective trial
comparing laparoscopic and robot-assisted radical nephrectomy
for localised disease, with a small sample size (n¼ 30) and follow-
up of less than a year (Hemal and Kumar, 2009). Outcomes in that
study and a handful of other retrospective series appear to be
equivalent (Asimakopoulos et al, 2014).
Post-operative recurrence rates for patients with locally
advanced (T3 and T4) disease are high, but despite this, the utility
of adjuvant treatment following has not yet been established.
Recent results of a planned interim analysis from the ASSURE
study comparing 1 year of adjuvant treatment with either sunitinib
or sorafenib vs placebo for patients with intermediate and high-risk
resected RCC have disappointingly shown no advantage for
disease-free survival or overall survival (OS; Haas and Manola).
A number of other adjuvant studies using other tyrosine kinase
inhibitors (TKIs) and the mammalian target of rapamycin (mTOR)
inhibitor everolimus are due to report within the next 2 years (Pal
and Haas, 2014). Although the results of these studies are awaited,
radiological surveillance is the standard of care for patients who
have undergone nephrectomy (Pal and Haas, 2014; Stewart et al,
2014).
One challenge cited within these adjuvant studies has been the
ability to accuratelypredict patients at high risk of recurrence, to
enrich the trial population. Recurrence risk stratification models
such as the Leibovich score rely on surgical staging and
histopathological features to categorise patients according to
recurrence risk (Leibovich et al, 2003; Table 2). Rini et al
(2015a) recently developed a 16-gene assay (11 cancer-related
and 5 reference genes) to stratify patients who had undergone
nephrectomy for localised RCC retrospectively, according to the
risk of recurrence. Patterns of gene expression were used to
re-classify patients into high, intermediate and low risk of renal
cancer recurrence. Interestingly, this led to 15% of stage 1 patients
being re-classified as high risk and conversely 19% of stage 2–3
patients being shown to be at low risk of recurrence. The
recurrence score improved on the ability of Leibovich score to
predict the risk of recurrence. Assessment of expression patterns
from multiple sites of single tumours showed consistent gene
expression patterns, although this was only performed for eight
patients (Rini et al, 2015a). This consistency is in contrast to the
work of Gerlinger et al (2012), who found that different biopsy
sites led to differing expression patterns. Further prospective
clinical evaluation of this approach is warranted. Such a strategy
may represent a prognostic biomarker able to enrich recruitment
to future adjuvant studies as well as guiding patient stratification in
therapeutic trials more widely.
MANAGEMENT OF OLIGOMETASTATIC DISEASE
Beyond surgery for early stage disease, there is a further role for
surgery in the management of oligometastatic disease. Resection of
oligometastatic disease can have a range of benefits in selected
patients including cure, prolonging survival, palliating symptoms
and delaying the need to commence systemic treatment (Kavolius
et al, 1998). Again the questions of how to select patients
appropriate for surgery, and how to time it can be a nuanced one.
There is evidence for improved outcome in patients with a longer
disease-free interval, and lung metastases are associated with a
better prognosis than those at other sites (Kavolius et al, 1998).
Our local approach is to operate on completely resectable
metastases that remain stable after a period of 3–6 months’
Table 1. Progression-free survival and overall survival by
AJCC stage after surgical resection for localised and locally
advanced RCC (Russo et al, 2008)
AJCC stage
5-Year
PFS (%) 95% CI
5-Year
OS (%) 95% CI
T1 95 93–97 87 85–90
T2 74 64–82 76 67–83
T3 81 76–85 72 67–77
T4 22 3–51 22 3–51
Abbreviations: CI¼ confidence interval; OS¼overall survival; PFS¼progression-free
survival.
Table 2. The Leibovich Score, an algorithm for predicting
metastases after radical nephrectomy (Leibovich et al, 2003)
Feature Score
Primary tumour status
pT1a 0
pT1b 2
pT2 3
pT3a 4
pT3b 4
pT3c 4
pT4 4
Regional lymph node status
pNx 0
pN0 0
pN1 2
pN2 2
Tumour size (cm)
o10 0
X10 1
Nuclear grade
1 0
2 0
3 1
4 3
Histologic tumour necrosis
No 0
Yes 1
Risk group (score)
5-Year metastasis-
free survival
10-Year metastasis-
free survival
Low (0,1,2) 97.1% 92.5%
Intermediate (3,4,5) 73.8% 64.3%
High (X6) 31.2% 23.6%
Staging is according to the 2002 AJCC TNM staging system. Patients can be stratified into
three risk groups: low risk (score 0–2), intermediate risk (score 3–5) and high risk (scoreX6).
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observation to exclude the possibility of early development of
multiple metastases.
There has been an emerging role for specialist imaging in this
field (Gerety et al, 2015) and there remains a need for biomarkers
to aid with the detection of occult metastatic disease (Tunuguntla
and Jorda, 2008; Gerety et al, 2015). Neither approach is currently
in routine clinical use. There is no evidence for the role of adjuvant
treatment following metastectomy and standard treatment is to
continue regular radiological surveillance of such patients.
MANAGEMENT OF ADVANCED DISEASE
The discovery of the underlying biology in ccRCC led to the
introduction a decade ago of drugs targeting the VEGF and mTOR
pathways, which became the standard of therapy for metastatic
RCC (mRCC). These targeted drugs, pazopanib, sunitinib,
sorafenib, axitinib, bevacizumab, everolimus and temsirolimus
transformed the management of mRCC after being shown to be
superior to cytokine therapy and placebo in pivotal phase 3 trials
(Escudier et al, 2007, 2014a; Hudes et al, 2007; Motzer et al, 2007,
2008, 2013; Rini et al, 2008; Sternberg et al, 2010).
Their widespread adoption ended an era in which cytokine
immunotherapy, with interferon-a (IFN-a) or high-dose inter-
leukin-2 (HD Il-2), was the only effective treatment option in
mRCC, only suitable for selected patients and with poor overall
response rates. Since the exciting period of the introduction of
these medications in the mid-2000s, progress plateaued in the
management of mRCC. Despite first- and second-line agents, 5-
year survival remains poor, and complete and durable responses
are rare.
CLINICAL PROGNOSTIC MODELS
Clinical prognostic models are important in treatment planning in
mRCC, guiding decisions ranging from whether to undertake a
cytoreductive nephrectomy to choice of therapy.
The Memorial Sloan Kettering Comprehensive Cancer Center
(MSKCCC) criteria were developed to predict survival in patients
with mRCC, using clinical factors including low Karnofsky
performance status, anaemia, elevated LDH, hypercalcaemia and
absence of prior nephrectomy to divide patients into prognostic
groups (Motzer et al, 1999). The model was refined in 2002 to
encompass all the risk factors named above, but replacing absence
of prior nephrectomy with time from initial RCC diagnosis to
commencement of therapy of o1 year (Motzer et al, 2002). The
MSKCC model was developed during the cytokine era, and was
subsequently validated in the TKI population era by Heng et al
(2009, 2013) who confirmed four of the five MSKCC criteria
(excluding elevated LDH) as independent predictors of poor
prognosis, and added neutrophilia and thrombocytosis as addi-
tional risk factors, with a median survival of 43.2, 22.5 and 7.8
months in the favourable, intermediate and poor prognostic
groups, respectively (Table 3).
TOWARDS PROGNOSTIC BIOMARKERS IN CCRCC
Patients with ccRCC demonstrate a wide range of clinical
behaviours, from indolent, slowly progressive oligometastatic
disease to aggressive, rapidly deteriorating phenotypes. There is
also a wide range of response to currently available therapies. There
is therefore much to be gained from developing prognostic and
predictive biomarkers. Currently, patients are stratified prognos-
tically according to clinical and laboratory parameters (Li et al,
2015), but there remains a huge gap in our knowledge of which
genetic and biochemical features within tumours drive the
differences. With a high frequency of VHL gene mutation in
ccRCC, this gene has made an attractive candidate for a possible
biomarker for patient outcome. Despite extensive evaluation there
is currently no evidence that the absence or presence of a VHL
mutation or the type of mutation has any predictive or prognostic
value in sporadic ccRCC (Hakimi et al, 2013; Gossage et al, 2015).
VHL inactivation alone is insufficient for the formation of RCC
(Gossage et al, 2015). The genetics of RCC is distinctive in that in
addition to mutations in VHL, these tumours have infrequent
somatic mutations in known common cancer genes, such as p53
and RAS (Dalgliesh et al, 2010). Three other tumour suppressor
genes have been implicated in the development of ccRCC;
polybromo 1 (PBRM1; 29–41%; Varela et al, 2011; Hakimi et al,
2013; Gossage et al, 2014), BRCA1-associated protein 1 (BAP1; 6–
15%; Pen˜a-Llopis et al, 2012; Hakimi et al, 2013; Gossage et al,
2014) and SET domain containing 2 (SETD2; 3–16%; Dalgliesh
et al, 2010; Duns et al, 2010; Hakimi et al, 2013; Gossage et al,
2014).
Interestingly, all three genes are involved in chromatin function
and are located close to 3p21. The loss of 3p, which is present in
490% of ccRCC would knock out one allele of all the three of
these tumour suppressor genes (Young et al, 2009). PBRM1
encodes the protein BAF180, which forms part of a chromatin
remodelling complex and depleting PBRM1 expression in ccRCC
cell lines using small interfering RNA led to the increased cell
proliferation (Varela et al, 2011). The BAP1 gene encodes a H2A
deubiquitinase, which deubiquitinates histones (Pen˜a-Llopis et al,
2012). SETD2 encodes a H3 lysine methyltransferase, which is
involved in the methylation of histones (Dalgliesh et al, 2010).
SETD2 knockout is embryonically lethal in mice due to the
disruption of embryonic vascular development (Hu et al, 2010).
All the three genes have been investigated as possible prognostic
biomarkers in ccRCC. Case series have unanimously found that
tumours with BAP1 mutations are associated with more aggressive
pathological features and a worse cancer-specific survival (Hakimi
et al, 2013). In another retrospective case series, BAP1 mutations
were associated with the presence of metastatic disease at
presentation and advanced clinical stage, when compared with
tumours with PBRM1 mutations (Gossage et al, 2014). In one
cohort of 145 patients with ccRCC between 1998 and 2011, median
OS was 4.6 years for patients whose tumours harboured BAP1
mutations vs 10.6 years for patients whose tumours harboured
PBRM1 mutations (Kapur et al, 2013).
Data regarding the impact of PBRM1 mutations have been
inconsistent, with another case series showing that small tumours
Table 3. The International Metastatic Renal-Cell Carcinoma
Database Consortium Model for prognosis in first-line
treatment for metastatic RCC (Heng et al, 2013)
Criteria
Karnofsky performance status o80%
Time from diagnosis to treatments o1 year
HboLLN
Corrected calcium 4ULN
Neutrophils4ULN
Platelets4ULN
Number of criteria Group Median overall survival
0 Favourable 43.2 months (95% CI 31.4–50.1)
1–2 Intermediate 33.5 months (95% CI 18.7–25.1)
3–6 Poor 7.8 months (95% CI 6.5–9.7)
Abbreviations: LLN ¼ lower limit of normal; ULN ¼ upper limit of normal.
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(o4 cm) with PBRM1 mutations were six times more likely to
attain pathological stage pT3a than pT1a (Hakimi et al, 2013).
Hakimi et al (2013) found no association between PBRM1 and
SETD2, and survival. BAP1 and PBRM1 mutations are almost
always mutually exclusive, occurring together at much lower
frequencies than would be expected statistically (Pena-LLopis et al,
2013; Joseph et al, 2016), but in case series, results for the minority
of patients with both mutations have been inconsistent. One case
series found that these patients had a worse outcome with a
median OS of 2.1 years, whereas in another case series found no
association between BAP1 and PBRM1 mutation status and OS,
and also no worsening of prognosis in patients with both
mutations (Kapur et al, 2013; Gossage et al, 2014). In a large
retrospective cohort of 1400 patients could be divided into four
distinct groups clinically based on their BAP1 and PBRM1
mutational status (Joseph et al, 2016). Patients with wild-type
BAP1 and PBRM1 had the best 10-year RCC-specific survival, with
a stepwise deterioration for patients with PBRM1 loss, followed by
those with BAP1 loss. In that case series, patients with the loss of
function of both genes had the worst clinical outcome (Joseph et al,
2016).
The mechanism by which these genes responsible for chromatin
remodelling may affect the biology of tumours is not understood,
but it is interesting to note that in an assessment of tumour
heterogeneity in ccRCC by Gerlinger et al (2012) found three
different mutations in SETD2 in different metastatic loci,
suggesting a role for these mutations as secondary events in the
development of an invasive and metastatic phenotype (Gerlinger
et al, 2012).
Overall, although a number of genes, including VHL, PBRM1,
BAP1 and SETD2 have been investigated as possible prognostic
biomarkers, there is at present no validated marker in clinical use.
CYTOREDUCTIVE NEPHRECTOMY
Cytoreductive nephrectomy was shown to confer an OS advantage
in mRCC during the cytokine era, and became an established
treatment option but its utility has yet to be proven in the context
of TKI treatment (Flanigan et al, 2004). An ongoing prospective
study in patients on sunitinib (CARMENA) is expected to report in
2019 (Clinicaltrials.gov, NCT0093033). Questions still remain over
the optimum timing for nephrectomy. The SURTIME study is
comparing upfront surgery, with surgery after a course of
neoadjuvant sunitinib (Clinicaltrials.gov, NCT01099423). Until
the results of these trials are available, cytoreductive nephrectomy
is offered for palliative reasons for pain or uncontrolled bleeding,
or in patients with good performance status with a large primary
and small volume metastatic disease (Escudier et al, 2014c).
SYSTEMIC TREATMENT OF ADVANCED RCC
A decade has passed since cytokine treatment with IFN and HD Il-
2 were superseded by drugs targeting the VEGF and mTOR
pathway based on pivotal phase 3 trials demonstrating their
superiority. The anti-VEGF TKIs sorafenib, sunitinib, pazopanib
and axitinib (Motzer et al, 2007, 2013; Sternberg et al, 2010;
Escudier et al, 2014a), and mTOR inhibitors everolimus and
temsirolimus (Hudes et al, 2007; Motzer et al, 2008) have the
advantages over cytokine treatment of a higher overall response
rate and a more favourable safety profile. Treatments currently
available or emerging in mRCC and their mechanisms of action are
summarised in Figure 1.
Endothelial cell
PDGFR
PDGF
Sunitinib
Sorafenib
Pazopanib
Axitinib
Bevacizumab
Tumour cell
MEK ERK
Raf
Ras
Pl3K
AKT
mTORC
Everolimus
Temsorilimus
Inactivated
PTEN
TSG
PD-L1
PD-1
Cabozantinib
T cell
HGF
MET
mRNA
translation
Cyclin D1
c-MYC
Transcriptional
activation of
target genes
Cell growth
and survivalNucleus
HIF
HIF
Hypoxia
Inactivated
VHL
TSG
Lenvatinib
VEGF
VEGF
VEGFR
VEGFR
CTLA-4
Ipilimumab
Nivolumab
Atezolizumab
Figure 1. Mechanism of action of treatments for RCC. Abbreviations: CTLA4¼ cytotoxic T-lymphocyte-associated antigen 4; HGF¼hepatocyte
growth factor; PDGF¼platelet-derived growth factor; PDGFR¼platelet-derived growth factor receptor; PD-1¼programmed cell death 1;
PDL-1¼programmed cell death ligand 1; VEGF¼ vascular endothelial growth factor; VEGFR¼ vascular endothelial growth factor receptor.
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TREATMENT SELECTION IN METASTATIC CCRCC
As the predominant histological type within RCC, this is the group
of patients for which there is the greatest evidence base to guide
management. Renal cell carcinoma can sometimes follow an
indolent course, therefore a period of observation can be
considered before starting treatment (Rini et al, 2014). Immediate
treatment is advised however where there is extensive multisite,
progressive or symptomatic disease. First-line treatment in mRCC
depends heavily on the prognostic category, with differing
recommendations for favourable and intermediate-risk disease vs
poor-risk disease.
MANAGEMENT OF FAVOURABLE/INTERMEDIATE-RISK
CCRCC
First-line treatment. Options for first-line treatment in favour-
able- and intermediate-risk ccRCC currently include the oral
multitargeted kinase inhibitors sunitinib and pazopanib, and the
recombinant anti-VEGF monoclonal antibody bevacizumab, in
combination with IFN-a.
Bevacizumab with IFN-a was approved in the first line in
mRCC based on two phase 3 trials, showing that the addition of
bevacizumab to IFN-a extended PFS to 8–10 months (vs 5 months;
Escudier et al, 2007; Rini et al, 2008), this option is significantly less
frequently used compared with the more convenient to administer,
oral TKIs. Therefore, the choice in the first-line setting is most
commonly between sunitinib and pazopanib.
Sunitinib has demonstrated superiority over IFN-a in a phase 3
trial with a significant improvement in PFS (11 months vs 5
months; Motzer et al, 2007). Pazopanib was approved after being
shown to be superior to placebo (9.2 months vs 4.2 months;
Sternberg et al, 2010) and subsequently non-inferior to sunitinib in
the first-line setting (Motzer et al, 2013). One striking feature of the
TKIs is that complete radiological responses are rare, with stable
disease being the most frequent best tumour response in the
registration trials, occurring inB39–50% of patients, with a partial
response as the next most common response in 19–31% (Motzer
et al, 2007, 2013; Escudier et al, 2014a).
In view of data showing equivalent efficacy for these two agents,
the choice between sunitinib and pazopanib is often based on the
differences in their side effect profiles. Sunitinib and pazopanib
share a number of side effects in common, including diarrhoea,
hypertension, fatigue, nausea and hypothyroidism (Motzer et al,
2013). In the PISCES crossover trial comparing sunitinib with
pazopanib, patient preference was in favour of pazopanib 70% vs
22%, whereas 8% expressed no preference (Po0.001; Escudier
et al, 2014b). Fatigue, hand–foot syndrome, stomatitis and
myelosupression are commoner with sunitinib treatment, whereas
clinically significant LFT derangement and hair colour changes are
more associated with pazopanib (Motzer et al, 2013). Pazopanib is
associated with higher rates of grade 3 or 4 LFT derangement (17%
vs 4%) and is therefore inadvisable in patients with pre-existing
bulky liver disease or baseline LFT derangement (Motzer et al,
2013). Our clinical practice is to counsel patients about both drugs
and base decision-making on their lifestyle and the acceptability of
the side effect profile of both drugs.
Management of treatment toxicities. The TKIs generally have
acceptable side effect profiles, but require careful monitoring and
management of side effects, to maintain optimal dosing and drug
exposure.
Biochemical evidence of thyroid abnormalities has been
reported with all TKIs, but are most common with sunitinib,
occurring in up to 70% of patients, with 15% requiring treatment
(Wolter et al, 2007; Motzer et al, 2013; Rini et al, 2015c). Patients
on all TKIs should have baseline thyroid function tests performed
before commencing treatment, and undergo regular surveillance
for thyroid abnormalities. Patients who develop overt hypothyr-
oidism (a raised TSH along with a low T4, and/or symptoms of
hypothyroidism, or both) require treatment with levothyroxine.
Hypertension is a well-recognised on-target side effect of anti-
VEGF treatments, occurring in patients receiving TKIs and also the
anti-VEGF monoclonal antibody bevacizumab, with a frequency of
17–40% reported in studies of these drugs (Rini et al, 2015d). It has
been proposed that treatment-associated hypertension could be an
on-treatment biomarker for response to anti-VEGF treatments
(Rini et al, 2011a). Several independent retrospective analyses in
patients taking sunitinib for mRCC have confirmed that patients
with hypertension have a more favourable response (Rini et al,
2011a; Izzedine et al, 2015). Patients who developed treatment-
induced hypertension (defined by a SBP of X140) had a longer
median OS (30.9 months vs 7.2 months) and the overall response
rate was also significantly higher in the hypertensive group (54.8%
vs 8.7%; Rini et al, 2011a).
There is interesting – albeit retrospective – data that the use of
angiotensin system inhibitors (ASI, ACE inhibitors and angioten-
sin II receptor blockers) is independently associated with an
improved response to anti-angiogenic treatment. A large retro-
spective pooled analysis of 4736 patients receiving treatment for
mRCC found that the use of ASI was significantly associated with
prolonged OS in patients receiving VEGF-directed therapy, but not
in those receiving mTOR inhibitors or IFN (McKay et al, 2015).
Median OS was 31 months in the ASI-treated patients vs 20
months in the non-treated patients. It is important to note that this
finding is based on retrospective, non-randomised data, and
further evaluation in a prospective study is warranted. In the
meanwhile, there is reasonable rationale for favouring ASI over
other anti-hypertensives in patients on treatment, unless there are
reasons to avoid doing so.
Diarrhoea is a class effect of TKIs, with reported frequency of
grade 3 and above diarrhoea between 5 and 13% reported for
sunitinib, pazopanib and axitinib (Motzer et al, 2007; Sternberg
et al, 2010; Escudier et al, 2014a). Milder diarrhoea is common,
occurring in approximately half of patients, and can be managed
with oral hydration and the administration of anti-motility agents
such as loperamide. There is emerging data to suggest that
treatable, reversible causes such as exocrine pancreas insufficiency
or bile acid malabsorption may underlie severe diarrhoea in a
subgroup of patients on TKIs. Our current clinical practice is to
actively screen patients for symptoms such as nocturnal diarrhoea
and steattorrhoea, which can be suggestive of these mechanisms
(unpublished data). Severe diarrhoea, grade 3 or above warrants
withholding treatment until symptoms resolve or return to grade 1.
After this, dose reduction is usually warranted.
The mucositis associated with TKIs is rarely severe enough to
warrant treatment interruption or dose reduction. Management is
symptomatic with good oral hygiene and dietary modification.
Traditional management of treatment toxicity with TKIs has
been to dose reduce, but adopting alternate treatment scheduling
may not only increase tolerability but also enhance oncological
outcomes. Standard treatment with sunitinib is 50mg once a day
for 4 weeks followed by a 2-week break. The dose of sunitinib is
reduced by increments of 12.5mg if this dose is not tolerated.
A retrospective Canadian series including 172 patients has
suggested that a more individualised approach to treatment
scheduling may not only improve tolerability but also improve
oncological outcomes (Bjarnason et al, 2014). Patients on a range
of alternate schedules – including 2 weeks on treatment followed
by a 1-week break – had superior OS and PFS compared with those
on standard scheduling (Bjarnason et al, 2014). A prospective trial
of this individualised approach to scheduling sunitinib is ongoing
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(clinicaltrials.gov, NCT NCT01499121). Once commenced on
TKIs, it is standard practice for patients to be treated continuously
until progression, although it is not known whether this approach
is superior to interrupted treatment. The ongoing STAR trial aims
randomises patients with locally advanced or metastatic ccRCC to
either continuous or interrupted treatment with either sunitinib or
pazopanib, according to physicians’ preference and is expected to
report in 2020 (Isrctn.com, ISRCTN06473203).
Second-line treatment. Patients who progress on first-line TKI
therapy have the option of either a second-line TKI (axitinib) or an
mTOR inhibitor, everolimus (Motzer et al, 2008; Rini et al, 2011b).
Mammalian target of rapamycin is a serine/threonine kinase that is
a downstream effector of the PI3K/AKT pathway. Targeting
mTOR is of particular relevance in RCC, because in the majority of
cases, the loss of pVHL leads to constitutive activation of the HIFs,
resulting in the upregulation of many HIF targets associated with
angiogenesis, metabolic adaption and metastasis, including VEGF.
Mammalian target of rapamycin has been found to increase HIF at
the translational level, therefore inhibition of mTOR can be seen to
be particularly useful in RCC (Batelli and Cho, 2011).
Everolimus was approved on the basis of the phase 3 randomised
RECORD-1 study, which compared everolimus with placebo for
patients with good- or intermediate-risk features (as per MSKCC
criteria), who had progressed on sunitinib or sorafenib (Motzer et al,
2008). A quarter of patients included had received prior treatment
with multiple TKIs and it was also permitted for patients have had
prior treatment with other agents including IFN and interleukin-2.
As a result, a large proportion of patients were receiving everolimus
in the third-line setting or later. The trial was stopped early after
interim results showed a doubling of PFS (4.0 months vs 1.9
months). The FDA approved everolimus on the basis of these results
for patients who have progressed on other targeted therapies.
Clinicians often base their choice of second-line therapy
between everolimus and axitinib on the response to the first-line
TKI. A retrospective series of 464 patients demonstrated no
association between the response to first-line TKI and response to
second-line TKI (Al-Marrawi et al, 2013). Another retrospective
series found that PFS of X12 months to first-line TKI predicted a
better response to second-line treatment, whereas a low albumin,
elevated serum LDH and elevated calcium were all predictors of a
poor response (Sacre´ et al, 2016). A number of biomarkers have
undergone evaluation, but there are none currently in clinical
practice to guide the choice of which therapeutic modality to use.
Recent trial evidence has led to an interest in the use of MET
inhibitors in the second line for ccRCC. c-MET is a proto-oncogene
on chromosome 7, which encodes a transmembrane tyrosine
kinase, the cell surface receptor for the growth factor hepatocyte
growth factor. Activating mutations in c-MET been identified in
hereditary and sporadic papillary RCC (pRCC) (Haas and
Nathanson, 2014). More recently, c-MET has also been shown to
be overexpressed in ccRCC, as a result of the loss of pVHL, and is
an independent negative prognostic marker (Gibney et al, 2013).
Cabozantinib is a small-molecule TKI, currently approved for
metastatic medullary thyroid cancer that inhibits VEGF, MET and
AXL; each implicated in the pathogenesis of RCC or the
development of resistance
Recent results of the phase 3 METEOR study in which the MET
inhibitor cabozantinib was compared with everolimus in patients
with ccRCC who had progressed after TKI therapy have added to
the considerable interest in harnessing this mechanism clinically
(Choueiri et al, 2015). Cabozantinib showed a significant PFS
advantage with a median PFS of 7.4 months vs 3.8 months for
everolimus. The hazard ratio (HR) for progression or death was
0.58 (95% CI 0.45–075, Po0.001). The interim threshold for
significance for OS was not met. This promising result suggests a
future role for cabozantinib as part of the ccRCC management
paradigm, likely displacing everolimus further down the treatment
hierarchy. Activation of the fibroblast growth factor pathway has
been suggested as a mechanism of resistance to TKIs. The anti-
FGFR and anti-VEGF TKI dovitinib showed no advantage in the
third line over sorafenib in patients previously treated with both a
TKI and mTOR inhibitor (Motzer et al, 2014). There remains a
significant unmet need for effective treatments to overcome
resistance to therapy.
MANAGEMENT OF POOR-RISK CCRCC
The use of temsirolimus as first-line treatment in poor-risk mRCC is
supported by a phase 3 trial in untreated patients with three out of
six predictors of poor outcome (including the five MSKCC criteria,
with the addition of metastases in multiple organs; Hudes et al,
2007). Patients were randomised to temsirolimus, temsirolimus plus
IFN-a or IFN-a alone. There was a significant improvement in OS
with temsirolimus compared with IFN-a or a combination of both
drugs. OS was 10.9 months for temsirolimus vs 7.3 months for IFN.
In a subgroup analysis, the benefit of temsirolimus was limited to
patients under the age of 65 (Hudes et al, 2007).
Although European guidelines recommend temsirolimus for
first-line treatment in poor-risk patients with mRCC, in practice
this treatment – administered as a weekly infusion – is very little
used in Europe (Escudier et al, 2014c). The trials that led to the
licensing of sunitinib, pazopanib and bevacizumab/IFN all
included a small cohort of poor prognosis patients (o10%),
making these drugs the more usually used first-line treatments, in
those patients fit enough to receive them (Escudier et al, 2007;
Motzer et al, 2007; Rini et al, 2008; Sternberg et al, 2010).
Axitinib is not currently available in the first line outside of
trials, but is currently being evaluated in the single arm A-Predict
study, in patients unsuitable for cytoreductive nephrectomy
according to physician discretion, and therefore likely to include
a significant cohort of poor-risk patients (Clinicaltrials.gov,
NCT01693822). Results are expected in the Autumn of 2016.
TREATMENT SELECTION IN NON-CCRCC
There is increasing recognition that non-clear cell variants of RCC
can be subdivided into distinct histological groups, with differing
underlying biology and clinical behaviour. Much of our knowledge
in this area arises from the study of hereditary RCC, and although
we are learning more and more about the molecular mechanisms of
these diseases, type-specific therapies are largely yet to be identified.
Patients with non-clear cell histology have been and continue to be
excluded from the majority of large therapeutic trials. As such, there is
a limited evidence base regarding choice of first and subsequent lines
of treatment in metastatic non-ccRCC. A fifth of patients in the
registration trial for temsirolimus had non-clear cell histology, and a
subgroup analysis showed that benefit of temsirolimus in this group of
patients was greater than in patients with clear cell histology (Dutcher
et al, 2009). For patients with clear cell histology and non-clear cell
histology, the HR for death or progression was with temsirolimus vs
IFN were 0.76 (95% CI 0.6–0.97) and 0.38 (95% CI 0.23–0.62),
respectively (Dutcher et al, 2009).
Further evidence for treatment selection in non-ccRCC comes
from recent results of the phase 2 ASPEN trial of everolimus vs
sunitinib in the first-line setting (Armstrong et al, 2016). The study
included patients with papillary (66%), chromophobe (15%) or
unclassified (19%) histology, and allowed patients of any MSKCC
risk group. Sunitinib was superior to everolimus overall with a PFS
of 8.3 months vs 5.6 months. However, an interesting differential
effect was seen according to histological subtype and MSKCC risk
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group. The results favoured sunitinib for good- and intermediate-
risk disease, and papillary or unclassified histology. However, for
MSKCC poor-risk disease or chromophobe histology, everolimus
was superior. These results provide some guidance for clinicians
selecting first-line treatments in patients with non-clear cell
histology, an area of clear unmet need.
Papillary RCC is the second most common histological type
after clear cell, accounting for 10–15% of cases of RCC. Hereditary
type 1 pRCC is caused by a germline mutation in the c-MET proto-
oncogene, and MET mutation or overexpression is commonly
found in sporadic pRCC also. There is therefore a good rationale
for the use of MET inhibitors in pRCC particularly type 1. Ongoing
phase 2 trials are assessing the role of the MET inhibitors
savolitinib, cabozantinib and crizotinib in pRCC (NCT02761057
and NCT02127710). Another phase 2 trial is examining the MET
inhibitor tivotinib (ARQ197) as a single agent, or in combination
with the epidermal growth factor receptor inhibitor erlotinib
(NCT01688973). Following the success of cabozatinib in the
second-line setting in ccRCC, in which MET has also been found
to be important, further study of MET inhibitors in pRCC are
clearly needed (Choueiri et al, 2015).
COMBINATION THERAPY
The only drug combination in current clinical use is bevacizumab
with IFN (Escudier et al, 2007; Rini et al, 2008). There is a good
rational for attempting dual targeting of both the mTOR and
VEGF receptor pathways in mRCC, but until recently results from
trials of this approach have been unsuccessful, with several negative
results from trials using this approach showing no clear benefit
from combining treatments, only an increase in toxicity.
However, recent success of the combination of the TKI
lenvatinib with everolimus in the second line has is the first
positive result for this strategy. Motzer et al (2015b) combined the
novel multitargeted TKI lenvatinib with everolimus, in a phase 2
study in patients with metastatic ccRCC who had progressed on a
first-line TKI. Patients were randomised to lenvatinib, everolimus
or a combination of both drugs. This trial showed a significant PFS
advantage for the combination arm vs single agent everolimus 14.6
months vs 5.5 months (P¼ 0.005). Progression-free survival was
7.4 months in the single agent lenvatinib arm, which was
significantly longer than for everolimus (P¼ 0.048). Rates of grade
3 or 4 toxicity were similar in the lenvatinib-containing arms and
higher than in the everolimus arms (45% for the combination, 44%
for lenvatinib and 38% in the everolimus group). The most
common toxicities in the combination group were diarrhoea,
reduced appetite and fatigue, and were manageable with dose
reductions. The significant PFS advantage of the combination arm
and its manageable toxicity profile, make lenvatinib–everolimus an
attractive treatment option over using these drugs sequentially.
RCC is generally highly resistant to cytoxic chemotherapy, but
there is some emerging evidence of efficacy when combined with a
TKI in sarcomatoid RCC. Michaelson et al (2015) reported a phase
2 study of the combination of gemcitabine with sunitinib in
patients poor-risk features, including patients with sarcomatoid
histology the combination was tolerated and showed some activity
and is currently being evaluated in a randomised study
(Clinicaltrials.gov, NCT01164228).
IMMUNOTHERAPY – TIME FOR A REPRISE
Spontaneous regressions of both localised and mRCC, although
rare are known to occur (Dickerson et al, 2015). Recognition of this
phenomenon – presumed to be immune mediated – led to the
interest in harnessing the immune system in the treatment of this
disease and ushered in an era when immunotherapy with IFN-a
and Il-2 was the mainstay of the treatment for mRCC (Raman and
Vaena, 2015), until the introduction of TKIs and mTOR inhibitors
in the mid-2000s.
Interleukin-2. High-dose interleukin-2 remains a therapeutic
option for highly selected groups of patients. Significantly, 70%
of the 10–15% of patients who show a complete response to Il-2
appear to have been cured after a long-term follow-up (Fyfe et al,
1996). Careful patient selection is highly important for this toxic
treatment with significant treatment-related morbidity and mor-
tality. McDermott et al (2015) published the SELECT trial in which
selecting patients for IL-2 by clinical features (clear cell, PS0) led to
a doubling of the response rate, compared with the historical
response rate. Predictors of poor response to Il-2 include papillary
histology, 450% granular cells or no alveolar features (Shablak
et al, 2011).
Cancer vaccines. Cancer vaccines are designed to enhance anti-
tumour immunity, by presenting tumour antigens to T cells. There
are several types of vaccine including autologous tumour cells,
peptide-based vaccines and dendritic cell (DC)-based vaccines. The
most promising vaccines in RCC have been peptide and DC based.
IMA901 is a peptide-based cancer vaccine, which presents
multiple tumour-associated peptides, with the aim of increasing
the number of tumour-specific T cells. The results of the phase 3
IMPRINT study were announced at ESMO 2015, with no survival
advantage to the addition of IMA901 to sunitinib vs sunitinib alone
(Rini et al, 2015b).
Dendritic cells are important antigen-presenting cells for the
induction of a T-cell immune response. Originating in the bone
marrow they infliltrate peripheral tissues – including tumour
tissues – in their immature form. In response to inflammatory
signals, DCs migrate to the lymph nodes presenting antigens to
T cells to stimulate an immune response. Dendritic cell-based
vaccines are labour-intensive to create, as an individual patient’s
DCs must be collected and cultured in vitro, primed with antigens
and then re-infused into the patient. The phase 3 ADAPT study
randomises patients to either sunitinib alone or sunitinib along
with AGS-003, an autologous DC-based vaccine (Clinicaltrials.gov,
NCT01582672), with results expected in April 2017.
T-cell checkpoint inhibitors. An increase in knowledge of the
biology of the immune response to cancer has led to the
development of a new class of treatments, the T-cell checkpoint
inhibitors (TCCIs; Figure 1). Programmed cell death 1 (PD-1) and
cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) are both
expressed on the surface of T cells and activation of these receptors
leads to a dampening of the T-cell anti-tumour response. Blockade
of these pathways with monoclonal antibodies against CTLA4
(ipilimumab) and PD-1 (nivolumab and pembrolizumab) or its
ligand, PDL-1 (atezolizumab), stimulates effector T cells to
enhance their anticancer response. The resulting loss of self-
tolerance means that the toxicities associated with these drugs are
primarily auto-immune in origin. Almost any organ can be
affected, although the gastrointestinal, skin, endocrine and
pulmonary effects predominate (Pham et al, 2015). The majority
of these side effects can be managed by treatment interruption and
immunosuppressive therapies when the severity warrants it (Pham
et al, 2015). It is vital that clinicians are vigilant for the broad range
of toxicities that can arise from these drugs, and the insidious
manner in which they can present, as they can, rarely, be fatal. The
largest experience of a TCCI (nivolumab) in RCC to date has
shown this drug to be relatively well tolerated in this patient
population, with a 19% grade 3 or 4 adverse event rate and no
fatalities (Motzer et al, 2015a).
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Clear cell RCC recently has recently joined the growing list of
cancers in which the PD-1 immune checkpoint inhibitor
nivolumab has been shown to improve OS (Motzer et al, 2015c).
The Checkmate025 study compared nivolumab with everolimus in
the second-line setting and demonstrated a clear OS advantage for
nivolumab (25.0 months vs 19.6 months; P¼ 0.0018) at an interim
analysis. The HR for death with nivolumab vs everolimus was 0.73
(98.5% CI, 0.57–0.93, P¼ 0.002) Complete responses were seen in
1% of patients on nivolumab, whereas flattening of the Kaplan–
Meier curves suggests enduring responses. Taken together, this is
encouraging evidence of rare cures, as well as the possibility of
long-term disease control for a minority of patients (Figure 2). This
can be contrasted with TKIs that produce short-term clinical
benefit in a large proportion of patients but with which sustained
and complete responses are rare.
Median PFS was modest and similar in both arms (4.6 months
vs 4.4 months; NS), although there was a late separation of the
curves. Subgroup analysis showed that these benefits applied to all
patients, including those in the poor-risk group, with some
suggestion that benefit from nivolumab was in fact greatest in this
group. Nivolumab was well tolerated, the rate of grade 3 and 4
adverse events was 19% vs 35% for everolimus.
The possibility that nivolumab may be more effective earlier in
disease is being explored by the first line, phase 3 CheckMate 214
study, which compares dual blockade of CTLA4 and PD-1 with
(nivolumab and ipilimumab) with sunitinib in the first line
(Clinicaltrials.gov, NCT02210117). The combination of TCCI with
anti-angiogenic monoclonal antibodies is being explored in a
number of ongoing studies. Pembrolizumab has been safely
combined with bevacizumab in a phase 1 study and a number of
other early phase studies are ongoing combining atezolizumab with
bevacizumab (Clinicaltrials.gov, NCT01984242), nivolumab with
bevacizumab (Clinicaltrials.gov, NCT02210117) and pembrolizu-
mab with aflibercept (NCT00298959; Dudek et al, 2016). Patients
with non-clear cell histology were excluded from the Check-
mate025 study, but now have access to nivolumab via an expanded
access program (ClinicalTrials.gov, NCT02596035).
TKIs remain the first-line treatment for the majority of patients
with mRCC, whereas the results of first-line studies are awaited.
However, it is likely that within a few years, TCCI will move into
the first line. What is unclear at present is the interaction between
TKIs and TCCIs, and optimal sequencing and combining of these
drugs. There is early evidence from patients who participated in the
nivolumab studies, who went on to receive TKIs and mTOR
inhibitors that these drugs retain their efficacy post TCCI (Albiges
et al, 2015). There is also some suggestion that nivolumab may lead
to enduring changes in the tumour microenvironment, which may
even enhance future response to further lines of these established
therapies.
The modest 25% objective response rate to nivolumab in
the CheckMate025 has significant room for improvement by
attempting to combine TCCI with other therapies including other
immunotherapies and anti-angiogenics. A number of early phase
trials have reported on combinations of TCCI with other agents,
and more are ongoing. There is a sound rationale for combining
TCCI with TKIs, potentially exploiting some of the immune
effects of sunitinib in particular. In RCC, there is a shift from type
1 to a type 2 cytokine immune response, with an accompanying
decrease in anti-tumour immunity. Sunitinib treatment
has been shown to shift the immune response from type 2 to
type 1 (Finke et al, 2008) and to decrease myeloid-derived
suppressor cells (Ko et al, 2009). The TKI-nivolumab arm of the
phase 1 CheckMate016 trial has reported outcomes for the
combination of nivolumab with either sunitinib or pazopanib
(Amin et al, 2014). Although the nivolumab–sunitinib combina-
tion was well tolerated, the pazopanib arm was closed due
to dose-limiting toxicities mostly related to hepatotoxicity
(Amin et al, 2014). Other early phase studies combining TKIs
with TCCI are ongoing including pembrolizumab–pazopanib
(NCT02014636), pembrolizumab–axitinib (NCT02133742) and
pembrolizumab–lenvatinib (NCT02501096). Another anti-PD-1
monoclonal antibody pidilizumab (CT-011) is being studied in
combination with a DC vaccine (clinicaltrials.gov, NCT01441765).
The nivolumab–ipilimumab arm of CheckMate016 has also
reported results (Hammers et al, 2015). As expected, due to their
overlapping toxicities, full doses of nivolumab and ipilimumab
(both at 3mg kg 1) were not tolerated. However, nivolumab
3mg kg 1 with reduced dose ipilimumab at 1mg kg 1 every 3
weeks, followed by nivolumab at 3mg kg 1 until progression was
reasonably well tolerated – with a 34% rate of grade three
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adverse events, mostly GI and hepatic. Further evaluation is
warranted to determine whether this combination in RCC
replicates the improvement in PFS seen in metastatic melanoma
(Larkin et al, 2015).
A natural development of the success in mRCC has also been to
trial Nivolumab pre- and post cytoreductive nephrectomy in the
ongoing ADAPTeR study (Clinicaltrials.gov, NCT02446860) and
as a neoadjuvant treatment in localised RCC (Clinicaltrials.gov,
NCT02575222).
It has been postulated that high expression levels of pro-
grammed cell death 1 ligand (PD-L1) on tumour cell surfaces may
be correlated with an enhanced response to nivolumab, as blockade
of this pathway restores anti-tumour immunity. Subgroup analysis
within the Checkmate025 dividing patients into those with more
than or o1% PD-L1 expression showed that both groups of
patients benefited from nivolumab (Motzer et al, 2015a). A reliable
predictive biomarker for selecting patients for nivolumab would be
hugely attractive, both to increase efficacy and keep control of the
high costs of this drug, which threaten to put them out of the reach
of many health systems.
CONCLUSION
In the mid-2000s, TKIs and mTOR inhibitors transformed the
management of mRCC, ending an era in which cytokine-based
immunotherapy was available to a minority of patients and
outcomes were bleak overall. A decade later, it appears that the
success of nivolumab in the Checkpoint025 trial is bringing the
management of RCC full circle, with a rebirth for immunotherapy.
The second line in mRCC – once a choice between axitinib and
everolimus – is suddenly looking decidedly more crowded. Phase 3
data for cabozantinib and nivolumab support new treatment
options for patients, whereas phase 2 data for combination
lenvatinib–everolimus encourage the expectation of more options
to come. Future studies will need to focus on a head-to-head
comparison of these new regimens, although it is likely that with an
OS advantage nivolumab will predominate in the second-line
setting, with first-line results also eagerly awaited. Complete
responses were seen in 1% of patients on nivolumab and as longer-
term follow-up data are awaited, it remains to be seen whether
these will translate into long-term cures.
Frustratingly, at this stage, we lack robust predictive biomarkers
or the type of ‘personalised’ medicine seen in some other cancers,
and it will surely be crucial for future studies to continue to try to
identify those patients most likely to benefit. This has never been
more important given the high cost of these emerging drugs and
the need to avoid unnecessary toxicities in patients unlikely to
benefit.
A number of gaps remain in the management of RCC – effective
adjuvant treatment for resected early stage disease, the develop-
ment of effective predictive and prognostic biomarkers, and
curative treatment for advanced disease. The fact remains that
despite a decade of established targeted therapy for RCC, the
median survival of patients with mRCC is remains under 3 years
with systemic therapy. The hope is that a decade from now novel
targeted and immunological therapies will have decisively
improved the outlook for patients with renal cell cancer.
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